Sign In
Buy IBRX
$7.18
-0.0500 (-0.692%)
At Close: Jun 03, 2026
Stock Market Today, Feb. 18: ImmunityBio Soars After EU Approves ANKTIVA for Bladder Cancer
05:17pm, Wednesday, 18'th Feb 2026
Expand NASDAQ: IBRX ImmunityBio Today's Change (41.36%) $2.49 Current Price $8.51 Key Data Points Market Cap $5.9B Day's Range $6.08 - $8.68 52wk Range $1.83 - $8.68 Volume 2.5M Avg Vol 27M Gross Marg
Why ImmunityBio Stock Is Soaring Today
01:50pm, Wednesday, 18'th Feb 2026
Immunotherapy Anktiva is now approved in 33 countries, with a slew of these approvals taking shape just this week. In markets where it's already been approved, the young treatment is experiencing stro
What's Behind The Jump In ImmunityBio Stock?
12:02pm, Wednesday, 18'th Feb 2026
The authorization by the European Commission allows ImmunityBio to establish a substantial commercial footprint across four regulatory jurisdictions in less than two years from its initial FDA approva
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the European Commission has granted conditional marketing authorization
ImmunityBio: The Story Surrounding Anktiva So Far
05:12am, Wednesday, 18'th Feb 2026
ImmunityBio commands a premium valuation on the promise of Anktiva, a chemo-free immunotherapy platform showing early efficacy and manageable safety. IBRX's Anktiva is FDA-approved for BCG-unresponsiv
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
05:16pm, Tuesday, 17'th Feb 2026
NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX). Such investors
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
11:17am, Tuesday, 17'th Feb 2026
/PRNewswire/ -- Equity-Insider.com News Commentary - More than 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NYSE: IBRX), a commercial stage immunotherapy company developing next generation therapies that drive immunological memory and restore immune c
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
06:56pm, Thursday, 12'th Feb 2026
NEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX). Such investors are advis
Rapid Innovation is Reshaping Oncology: Stocks in Focus
09:01am, Thursday, 05'th Feb 2026
Rapid advances in immunotherapy, targeted drugs & artificial intelligence-driven research are reshaping oncology, spotlighting select cancer stocks to watch now.
ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas
07:00am, Monday, 02'nd Feb 2026
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the launch of ResQ215B, a Phase 2 clinical study evaluating a novel ch
Analyzing Gyre Therapeutics (NASDAQ:GYRE) and ImmunityBio (NASDAQ:IBRX)
01:44am, Monday, 02'nd Feb 2026
ImmunityBio (NASDAQ: IBRX - Get Free Report) and Gyre Therapeutics (NASDAQ: GYRE - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies b
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
10:00am, Thursday, 29'th Jan 2026
NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX). Such investors are advised
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
12:40pm, Tuesday, 27'th Jan 2026
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX). Such investors
Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer
05:02pm, Monday, 26'th Jan 2026
Expand NASDAQ: IBRX ImmunityBio Today's Change (-3.72%) $-0.24 Current Price $6.21 Key Data Points Market Cap $6.4B Day's Range $6.16 - $6.75 52wk Range $1.83 - $8.28 Volume 37M Avg Vol 23M Gross Marg
